S(+)-MA5 Enantiomer for Mitochondrial NAD+ Activation
Solution Overview
Problem
The racemic form of 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxo-butanoic acid (MA5) has limitations in increasing NAD+ levels in animal cells and activating mitochondrial function, with the R(-) form being metabolized into toxic substances and having higher cytotoxicity compared to the S(+)-form.
Innovation Solution
The S(+)-form of MA5, substantially free of the R(-) form, is used to increase NAD+ levels and activate mitochondrial function, with a high enantiomeric excess of at least 97%, stored under protective conditions, and formulated as a pharmaceutical or food composition to treat mitochondrial diseases and aging-related symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the racemic form of MA5 is used, then the compound can be administered to increase NAD+ levels and activate mitochondrial function, but the R(-) form is metabolized into toxic substances and has higher cytotoxicity
Solution Approach 1:
The racemic mixture of MA5 is separated into its two enantiomeric components, S(+)-MA5 and R(-)-MA5, through chiral resolution. This segmentation allows the beneficial S(+)-form to be isolated and used alone, eliminating the harmful effects of the R(-)-form while preserving the therapeutic benefits of increasing NAD+ levels and activating mitochondrial function.
Solution Approach 2:
The harmful R(-)-form is extracted and removed from the therapeutic composition. By using only the S(+)-enantiomer with enantiomeric excess of at least 97%, the patent extracts and eliminates the source of cytotoxicity and toxic metabolite formation, while retaining the therapeutic compound's ability to increase NAD+ levels and improve mitochondrial function.
2Productivity
If the racemic form of MA5 is used, then the compound can be synthesized and administered, but the therapeutic effect is limited due to the presence of both enantiomers
Solution Approach 1:
The racemic mixture is segmented into individual enantiomers through chiral resolution techniques. This segmentation enables the isolation of the therapeutically superior S(+)-form, achieving high enantiomeric purity (≥97%) that maximizes productivity in terms of therapeutic effectiveness while eliminating the diluting and harmful effects of the R(-)-form.
Solution Approach 2:
The enantiomeric composition parameter is changed from a 1:1 racemic mixture to a highly enriched S(+)-form with enantiomeric excess of at least 97%. This parameter change transforms the compound's therapeutic profile, significantly improving effectiveness in increasing NAD+ levels and activating mitochondrial function while reducing cytotoxicity.
3Reliability
If the S(+)-form of MA5 is used with high enantiomeric excess, then cytotoxicity is reduced and NAD+ levels are effectively increased, but the manufacturing process becomes more complex
Solution Approach 1:
The chiral resolution process segments the racemic mixture into separable enantiomeric components using chiral chromatography or other resolution techniques. This segmentation, while adding process steps, enables the production of high-purity S(+)-form with improved safety and efficacy profiles, justifying the increased manufacturing complexity through superior therapeutic outcomes.
Solution Approach 2:
Chiral resolving agents or chiral stationary phases are introduced as intermediaries to facilitate the separation of enantiomers. These intermediary substances enable the complex but necessary chiral resolution process, allowing the S(+)-form to be isolated with high enantiomeric purity for safe and effective therapeutic use.
Data Source
AI summary
An S(+) form of 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxo-butanoic acid or a physiologically acceptable salt thereof may be useful as an active ingredient of a pharmaceutical composition or a food or drink composition, and the like. An enantiomeric excess of an S(+) form may be at least 97% or more. The compound may be used in treating, improving, or preventing a mitochondrial disease and/or a symptom or a disease associated with aging.



